April Christensen points out the significance of finding the right practice manager organization and the resources they have to offer.
April Christensen speaks to how practice managers need to adjust to the ever-changing oncology market.
Randomized Phase 3, Multicenter, Open-Label Study Comparing Evofosfamide (EVO) in Combination with Doxorubicin (D) versus D Alone in Patients with Advanced Soft-Tissue Sarcoma (STS): Study TH-CR-406/SARC021
This randomized phase 3 study compared the efficacy and safety of evofosfamide (EVO) plus doxorubicin (D) with D alone in patients with locally advanced unresectable or metastatic STS previously untreated with chemotherapy for advanced disease. Patients on EVO+D could receive [ Read More ]
Real-Life Clinical Outcomes of Pazopanib Treatment in Patients with STS: A Japanese Musculoskeletal Oncology Group Study
The efficacy and safety of pazopanib were assessed in 156 Japanese patients with relapsed soft-tissue sarcoma (STS). This was a retrospective study based on postmarketing surveillance data. To be included in this study, patients’ primary tumor had to arise from [ Read More ]
This open-label phase 2 trial assessed the activity, safety, and tolerability of axitinib 5 mg orally twice daily in patients with advanced soft-tissue sarcoma (STS) who were unsuitable for or relapsed after standard chemotherapy. This report focuses on patients with [ Read More ]
Prognosis of Patients Receiving First-Line Chemotherapy for Advanced Soft-Tissue Sarcomas (STSs) with Locally Advanced vs Distant Metastasis vs Both: An EORTC-STBSG Database Analysis
The goal of this European Organisation for Research and Treatment of Cancer (EORTC) study was to study differences in prognosis between subgroups of patients who received first-line chemotherapy for advanced STS. This retrospective database analysis included 2473 patients who received [ Read More ]
Safety Profile of Trabectedin in Patients with Advanced Soft-Tissue Sarcoma (STS) Who Relapsed after Chemotherapy: Global Expanded Access Program Data
Study ET743-SAR-3002, an expanded access program, provided trabectedin to patients with incurable soft-tissue sarcoma (STS) following disease progression with standard therapy and represents one of the largest databases of pretreated STS patients. Prior efficacy and safety data from this study [ Read More ]
The combination of trabectedin and anti–PD-1 therapy may synergistically attack tumor cells and promote antitumor immunity. This pilot feasibility study was conducted to assess the safety, toxicity, and efficacy of this combination in patients with advanced soft-tissue sarcoma (STS). Each [ Read More ]
Trabectedin in Patients with Advanced Soft-Tissue Sarcoma (STS) Who Are Unfit for Standard Chemotherapy
The activity and tolerability of trabectedin has been widely studied in the second-line STS setting, but few studies evaluate it as first-line therapy for patients with comorbidities that preclude anthracycline-based chemotherapy. This study, TR1US, assessed the efficacy, tolerability, and pharmacokinetics [ Read More ]
Endoglin is upregulated following VEGF inhibition and may mediate resistance to pazopanib. A phase 1b/2a study of TRC105, an endoglin antibody, combined with pazopanib in patients with advanced soft-tissue sarcoma (STS) was reported at ASCO 2016. Based on activity in [ Read More ]